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Abstract
Structurally, Group 1 LILR (Leukocyte Immunogloblin (Ig)-Like Receptor, also known as Ig-like transcripts, ILT; Leukocyte Ig-
like receptor, LIR; and CD85) members are very similar in terms of the HLAIs (human leukocyte antigen class I molecules)
binding region and were hypothesized that they all bind to HLAIs. As one of the Group 1 LILRs, LILRA3 is the only secretory
LILR and may greatly control the inhibitory immune response induced by LILRB1, LILRB2, and other HLA-binding LILR
molecules like LILRA1. Nevertheless, little was known about the binding of LILRA3 to HLAIs. In this report, we present the
crystal structure of the LILRA3 domain 1 (D1) and evaluate the D1 and D1D2 (domain 1 and domain 2) binding to classical
and non-classical HLAIs using BIAcoreH surface plasmon resonance analysis (SPR). We found that LILRA3 binds both classical
HLA-A*0201 and non-classical HLA-G1 but with reduced affinities compared to either LILRB1 or LILRB2. The polymorphic
amino acids and the LILRA3 D1 structure support this notion.
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Introduction
Immune cells express activating and inhibitory receptors on
their surfaces to allow an adequate immune response. The
corresponding ligands binding to activating or inhibitory receptors
induce and modulate innate and adaptive immunity [1,2]. Human
chromosome 19q13.4 contains important immune cell receptor
genes [3], such as killer cell inhibitory receptors (KIRs), leukocyte
immunoglobulin (Ig)-like receptors (LILRs), leukocyte associated
Ig-like receptors (LAIRs) and the Fca receptor (FcaR).
LILRs [4,5,6] are also called Ig-like transcript (ILT) or
leukocyte Ig-like receptor (LIR) or CD85 and are closely related
to KIRs but expressed on the surface of a more broad range of
cells (i.e., on lymphoid and/or myeloid cells). There are 13
members (two of them are believed to be pseudogenes) of either
activating or inhibitory receptors in the LILR family [7]. LILR
family members contain either two or four C2-type Ig-like
domains in their extracellular portions (D1, D2, D3, and D4).
With the exception of LILRA3, activating receptors (LILRA1–A6)
contain a short cytoplasmic tail after the transmembrane domain.
They lack any signaling motif but recruit the c-chain of FceRI
through a charged arginine residue in the transmembrane domain
and deliver an activating signal through the c-chain cytoplasmic
immunoreceptor tyrosine-based activating motif (ITAM). In
contrast, inhibitory receptors (LILRB1–B5) have a long cytoplas-
mic tail containing immunoreceptor tyrosine-based inhibitory
motif (ITIM) and transduce an inhibitory signal. LILRA3 is the
only secreted soluble LILR lacking the transmembrane and
cytoplasmic domains [8,9].
It was suggested [10] that LILRs can be categorized into 2
groups according to the amino acid sequence similarity of the
region responsible for binding to human leukocyte antigen
(HLA). As opposed to Group 2 LILRs, Group 1 members
display high sequence similarity and are predicted to bind to
HLA class I molecules (HLAIs) [11,12,13]. Among the 13 LILRs,
LILRB1, B2, A1, A2, and A3 belong to Group 1. It is well known
that LILRB1 and LILRB2 bind to a broad range of classical and
non-classical HLAIs [13,14,15] and major histocompatibility
complex (MHC) class I-like molecules, such as UL18 [16].
Furthermore, LILRA1 binding to HLA-B27 has been reported
[17], but a LILRA2 domain-swapped dimer structure [18] is
unable to bind any HLAIs. However, among the Group 1
members, only LILRA3 has not been examined in detail
concerning HLAI binding.
It was previously proposed [18,19] that the crucial residues that
govern binding of Group 1 LILRs to HLAIs are Lys42 and Lys43
(KK), Ile47 and Thr48 (IT), and Leu54 and Val55 (LV) in the D1
domain, and that the hydrophobic 310 helices formed by these
residues appropriately orient the key residues for HLA binding.
Both LILRB1 and LILRB2 of Group 1 LILRs have these crucial
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19245residues in the D1 domain and truly bind to at least 3 alleles of
classical and non-classical HLAIs [20]. Meanwhile, LILRA2 [18]
as Group 1 LILRs, and LILRB4 [21] and LILRA5 [22] as Group
2 LILRs have no these residues in the D1 domain. Indeed, there is
no so called ‘‘hydrophobic core’’ by strands-helices transition in
the D1 domain of these LILRs. In contrast, LILRA1 and LILRA3
have the above-mentioned conditions for binding to HLAIs
(Fig. 1). However, the structure and evaluation of LILRA3 binding
to HLAIs are required to confirm this hypothesis. Further,
LILRA3 is the only non-membrane-bound LILR, and its function
was predicted to be antagonistic with HLA-binding Group 1
LILRs [23]. Recently, LILRA3 is implicated in the possible
pathogenesis of Psoriasis [24], multiple sclerosis [25], Sjogren’s
syndrome [26] and rheumatoid arthritis [27], indicating its
potential significant functions in autoimmune diseases. Thus, from
both the structural and functional points of view, it would be
interesting to determine if LILRA3 interacts with HLAIs. Though
two domains (D1 and D2) take part in the interaction between
LILR and HLAIs, previous studies [28,29] and the co-crystal
structures of HLA-A*0201 with LILRB1 [10] and HLA-G1 with
LILRB2 [30] indicate that the main contacts (nearly 75% of them)
are contributed by the first domain, D1.
Here, we report the binding properties of the LILRA3 D1 and
D1D2 domains to HLAIs (classical HLA-A*0201 and non-classical
HLA-G1) as analyzed by BIAcoreH surface plasmon resonance
(SPR) analysis, as well as the crystal structure of the LILRA3 D1
domain. We found that LILRA3 binds both classical and non-
classical HLAIs as predicted, but with reduced affinities relative to
LILRB1/B2. Further, the LILRA3 D1 crystal structure clearly
displays conformational changes in the residues responsible for the
binding of Group 1 LILRs to HLAIs, which greatly affects the
binding affinity to HLAIs.
Results
Soluble protein characterization and BIAcoreH binding
LILRA3 is a soluble protein, the only secreted member of the
LILR family, and contains four Ig-like domains (D1, D2, D3, and
D4). The full-length sequence encoding LILRA3 was cloned from
a human lymphocyte cDNA library (Strata Gene), and the
fragments encoding the LILRA3 D1 or D1D2 regions were
cloned from the full-length LILRA3 gene. Based on the previous
observation that the first two domains (D1 and D2) of Group 1
LILRs are responsible for binding to HLAIs and to determine if
LILRA3 interacts with HLAIs, the first or first and second N-
terminal domains of LILRA3 (D1, residues 1–97; and D1D2,
residues 1–197, respectively) were expressed in Escherichia coli
(Fig. 2A and 2B), followed by purification from inclusion bodies,
and renaturation via dilution refolding method. Size-exclusion of
the refolded materials and SDS-PAGE analysis (Fig. 2C)
indicated the correct molecular weight of the single and double
Ig-domains [31]. Similarly, far UV circular dichroism (CD)
spectra indicated that each sample was mainly comprised of b-
sheet secondary structure (data not shown). Thus, the two
proteins, LILRA3 D1 and D1D2, were successfully refolded,
purified with high purity, and used to evaluate the binding of
LILRA3 to HLAIs.
We used SPR to compare LILRA3 D1 and D1D2 with LILRB2
for the binding to HLA-A*0201 and HLA-G1. It was previously
reported [20,32] that LILRB2 binds a broad range of classical
HLAIs (HLA-A*1101, -B*3501, -C*0401, and -Cw*0702) with
affinities (Kd) ranging from ,14 to ,45 mM and also binds a non-
classical HLA (HLA-G1) with a higher affinity (Kd<5 mM). First,
we evaluated the binding affinity of LILRB2 to HLA-A*0201 and
HLA-G1. LILRB2 D1D2 was injected over the CM5 sensor
surface on which HLAIs were immobilized using standard amine
Figure 1. Multiple amino acid sequence alignment of the D1 and D2 domains of Group 1 LILRs. The secondary structure elements of
LILRA3 D1 are shown above the sequences. The asterisks indicate the residues involved in the HLAIs binding of LILRB1 and LILRB2 (blue for LILRB1
and yellow for LILRB2). The residues previously hypothesized to be critical to form the 310 helices region in domain 1 of Group 1 LILRs are demarcated
with green.
doi:10.1371/journal.pone.0019245.g001
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constants of LILRB2 D1D2 binding to HLA-A*0201 and HLA-
G1 were 9.74 and 5.62 mM, respectively, the latter being similar to
the previously reported HLA-G1 value [20,32]. Using the same
conditions, LILRA3 D1 and D1D2 were injected over the CM5
sensor surface on which HLAIs were immobilized, and the results
are shown in Figure 3C–3F. Both LILRA3 D1 and D1D2 bound
to HLA-A*0201 and HLA-G1 with affinities in the range of 20–
40 mM. Previous research evaluating the direct binding of LILRs
to HLAIs [20] demonstrates that Group 1 LILRs bind with a
higher affinity to non-classical than classical HLAIs. Our
experiment reconfirmed this trend. For HLA-G1, LILRA3
D1D2 showed a reduced binding affinity (Kd=14.6 mM) than
LILRB2 D1D2 (Kd=5.62 mM), and for HLA-A*0201, it showed a
further reduced binding affinity (Kd=28.5 mM) similar to that of
LILRA3 D1 binding to HLA-G1 (Kd=26.8 mM). Meanwhile,
LILRA3 D1 displayed much lower binding affinity to HLA-
A*0201 (Kd=40.1 mM) but still reached the binding affinity range
of CD8 (,100 mM).
To rationalize the structural basis for the binding of LILRA3 to
HLAIs, we attempted to characterize the structure of LILRA3 in
the HLA-binding region. However, despite using identical
refolding and purification procedures, all efforts failed to yield
any diffractive crystals of LILRA3 D1D2, and thus, only LILRA3
D1 could be crystallized.
Crystal structure of the LILRA3 D1 domain
The overall structure of the LILRA3 D1 domain has
characteristics consistent with Ig-like domain structures and also
displays properties unique to the LILR family (Fig. 4A). The
structure is primarily composed of b strands arranged into two
anti-parallel b sheets, with one b sheet containing three anti-
parallel b strands (A, B and E) and the other containing four anti-
parallel b strands (C, F, G and A9) [18]. Like the crystal structure
of LILRB1 D1D2 [28] and B2 D1D2 [33], the D1 structure of
LILRA3 also has a pocket-type hydrophobic core surrounded by
the C and E strands and two 310 helices between the two strands
(Fig. 4A).
Most of the hydrophobic residues on the strands and the 310
helices face toward the interior of this hydrophobic core, which
causes the hydrophilic residues on the adjacent loop region to
protrude outside of the core. This hydrophobic core not only
contains some important residues for direct binding to HLAIs but
also pushes the adjacent hydrophilic residues (e.g., Tyr38, Glu40,
Lys41, Lys42 and Glu68) to assume a proper conformation for its
binding to HLAIs, unlike the residues of Group 2 members and
LILRA2, where the two 310 helices between the C and E strands
cannot be seen by helix-strand transitions (Fig. 4B). Thus, via the
crystal structure of LILRA3 D1, we demonstrated that LILRA3
D1, like LILRB1 and B2, contains a hydrophobic core (as
previously predicted [18]) and is able to interact with HLAIs.
There is also a disulfide bond between cysteine residues 26 and 75,
which clearly indicates that of the two neighboring cysteines
(Cys74 and Cys75) in LILRA3 D1, Cys75 provides the correct
conformation for native structure through its disulfide bond
between the B and F strands.
LILRA3 D1 has a high level (.80%) of amino acid sequence
identity with LILRB1 and B2. Figure 4C and 4D show the
superimposed D1 structures between LILRA3 and LILRB1/B2.
In these overlays, LILRA3 D1 is more similar to LILRB1
(RMSD=0.348 for 1G0X, 0.336 for 1UFU) than LILRB2
(RMSD=0.857 for 2GW5). There are some differences around
the 78–83 loop region between LILRA3 D1 and LILRB1 D1
(Fig. 4C) and differences around the 29–33 and 77–83 loop
Figure 2. SDS-PAGE analysis of the inclusion body preparations and size exclusion chromatography profiles of LILRA3 D1 and
D1D2. A. Induction of LILRA3 D1D2 by ITPG. The first two lanes are the samples before IPTG induction, and the next two are the samples after
induction. The last lane is the molecular weight standard (shown in kDa). B. Induction of LILRA3 D1 by ITPG. The first three lanes are the samples
before induction, and the next three are the samples after IPTG induction. The last lane is the molecular weight standard (shown in kDa). C. Size
exclusion chromatogram showing LILRA3 D1 and D1D2 elution profiles by Superdex 75 10/300 GL column (GE Healthcare). The profiles are marked
with the approximate positions of molecular mass standards of 43.0, 29.0, and 13.7 kDa. The size exclusion chromatogram and 12% SDS-PAGE
separation profile (inset) of LILRA3 D1 and D1D2 fractions indicated that pure proteins were obtained as monomers.
doi:10.1371/journal.pone.0019245.g002
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the loop regions display some differences between LILRA3 and
LILRB1/B2, the amino acids in these regions do not participate in
binding to HLAIs. Therefore, the differences in these regions may
not affect the binding of LILRA3 to HLAIs.
Structural basis for the interaction of LILRA3 with
classical and non-classical HLAIs
Previous studies using cytolysis or immuno-staining have not
detected any significant binding of LILRA3 to HLAIs [13,23], but
our study using BIAcoreH SPR demonstrated that LILRA3 binds
Figure 3. BIAcoreH surface plasmon resonance analysis of LILRBA3 D1 and D1D2 monomer binding to immobilized HLA-A*0201
and HLA-G1. A. Kinetic analysis of the LILRB2 D1D2 monomer binding to the immobilized HLA-A*0201 (as a positive control). Protein at the
indicated concentrations was injected through the HLA-A*0201-immobillzed flow cells (700 response units (RU)). B. Kinetic analysis of the LILRB2
D1D2 monomer binding to the immobilized HLA-G1 (as a positive control). Protein at the indicated concentrations was injected through the HLA-G1-
immobilized flow cells (300 RU). C. Kinetic analysis of the LILRA3 D1D2 monomer binding to immobilized HLA-A*0201. D. Kinetic analysis of the
LILRA3 D1D2 monomer binding to immobilized HLA-G1. E. Kinetic analysis of the LILRA3 D1 monomer binding to immobilized HLA-A*0201. F. Kinetic
analysis of the LILRA3 D1 monomer binding to immobilized HLA-G1.
doi:10.1371/journal.pone.0019245.g003
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(HLA-G1) with reduced binding affinity compared to LILRB1/
HLA-A*0201 and LILRB2/HLA-G1 binding. Figure 5 shows the
superposition of LILRA3 D1 with LILRB1/HLA-A*0201 (5A)
and LILRB2/HLA-G1 (5B). Because the hydrophobic core
composed of the C and E strands and the two 310 helices between
the strands provide the necessary conformation of the residues to
interact with HLAIs, the important hydrophobic and polar
interactions in these regions of LILRB1/HLA-A*0201 and
LILRB2/HLA-G1 are conserved (Fig. 5A and 5B). LILRA3
Tyr38 forms hydrophobic interaction with the hydrophobic
residues of the A-B loop of the a3 domain of HLA-A*0201
(Val194, Ser195, and Asp196) and the B strand of the a3 domain
of HLA-G1 (Tyr197 and Glu198). Further, there may be a p-
cation interaction between Lys91 of the b2m of HLA-A*0201 and
Trp67 of LILRA3 D1, as seen with LILRB2 D1. The NH3
+ of
Lys91 in the b2m of HLA-A*0201 deeply intrudes into the
aromatic ring of LILRA3 D1 Trp67, thereby strengthening the
interaction between the two residues. As the distance between the
Trp67 of LILRA3 D1 and the G strand of the HLA-A*0201 b2m
becomes more intimate, Trp67 forms hydrophobic interactions
with the hydrophobic residues (Ile92 and Val93) on the G strand
of b2m. In the superimposed structure of LILRA3 and LILRB2/
HLA-G1, the hydrophobic interactions of LILRB2 Ser43 with the
residues (Val194 and Val248) of the a3 domain of HLA-G1 are
also conserved as LILRA3 D1 Thr43 interacting with the same
residues. Commonly existing interactions in both LILRB1/HLA-
A*0201 and LILRB2/HLA-G1, such as the Gly97 (LILRB1/B2)-
Ser88 (b2m of HLA-A*0201/G1) interaction (hydrogen bond) and
Gln18 (LILRB1/B2)-Gln89 (b2m of HLA-A*0201/G1) interac-
tion (hydrogen bond), are also conserved in the interaction
between LILRA3 D1 and HLA-A*0201/G1. Thus, the crystal
structure of LILRA3 D1 clearly indicates that LILRA3 would bind
to both HLA-A*0201 and HLA-G1.
Meanwhile, structural explanations exist for the reduced
binding affinity of LILRA3 for HLA-A*0201. Some polar
interactions may not exist in the LILRA3 D1/HLA-A*0201
complex (Fig. 5A) because the amino acids at positions 36 and 76
were replaced with histidine and isoleucine from arginine
(Arg36RHis36) and tyrosine (Tyr76RIle76). Thus, the salt bridge
between Arg36, Tyr76 of LILRB1 and Asp196 of the a3 domain
of HLA-A*0201 would be impossible in the LILRA3 D1/HLA-
A*0201 interaction. Again, the crystal structure of LILRA3 D1
displays that Lys42 forms a hydrogen bond with Glu68 of LILRA3
D1, rendering Lys42 unable to bind to Asp96 of the a3 domain of
HLA-A*0201. Indeed, the lack of polar interactions in the
LILRA3 D1/HLA-A*0201 complex would reduce the binding
affinity between these molecules. However, in the interaction
between LILRA3 D1 and HLA-G1, most of the polar interactions
are conserved (Fig. 5B). The superposition of LILRA3 D1 with
LILRB2 D1D2/HLA-G1 shows a strong polar interaction with
Tyr197 of the a3 domain of the heavy chain of HLA-G1. Both
Figure 4. Hydrophobic pocket of LILRA3 D1 and comparison of the crystal structures of LILRA3 D1, LILRB1 D1, and LILRB2 D1. A. The
hydrophobic pocket of LILRA3 D1. The hydrophobic residues located around this area are colored with magenta. B. The helix-strand transition
between LILRB1/LILRB2/LILRA3 and LILRA2/LILRA5: magenta, LILRA3; cyan, 1GOX (LILRB1); green, 1UFU (LILRB1); yellow, LILRB2 in complex with HLA-
G1 (2DYP); orange, 2D3V (LILRA5); and light pink, LILRA2 C. The difference in the loop region of the LILRA3 D1 (pink) superposed on LILRB1 D1D2
(1GOX-green and 1UFU-blue). D. The difference of the loop region of LILRA3 D1 (pink) superposed on the LILRB2 D1D2 (2GW5-yellow).
doi:10.1371/journal.pone.0019245.g004
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Tyr197 of the a3 domain of the HLA-G1. Residue 43 of LILRA3
D1 is Thr, while in the LILRB2 D1, it is Ser, and there is a
hydrogen bond between Ser43 of LILRB2 D1 and Glu198 of the
HLA-G1 a3 domain. Because the hydroxyl of LILRA3 D1 Thr43
is oriented more closely toward Thr200 than Glu198 of the a3
domain of HLA-G1 (as compared to the hydrogen bond between
Ser43 of LILRB2 D1 and Glu198 of the a3 domain of HLA-G1),
Thr43 of LILRA3 D1 is able to form a hydrogen bond with
Thr200 of the a3 domain of HLA-G1. LILRA3 Lys42 can also
potentially form a hydrogen bond with Glu229 of the light chain of
HLA-G1, as well as Glu68 of LILRA3 D1 itself. Thus, almost all
polar interactions between HLA-G1 and LILRB2 D1 are
conserved or compensated if LILRB2 D1 is replaced with
Figure 5. Comparison of the polar and hydrophobic interactions in the superposition of LILRA3 D1 (pink) to LILRB1/HLA-A*0201
(green) and LILRB2/HAL-G1 (yellow). A. The superposition of LILRA3 D1 to LILRB1/HLA-A*0201. Cyan and brown represent the a3 domain and
the b2m of HLA-A*0201, respectively. The yellow dotted line represents the polar interaction between the residues of LILRB1 D1 and that of HLA-
A*0201. The pink dotted line represents the polar interaction between the residues of LILRA3 D1 and that of HLA-A*0201. B. The superposition of
LILRA3 D1 to LILRB2/HLA-G1. Cyan and brown represent the a3 domain and the b2m of HLA-G1, respectively. The yellow dotted line represents the
polar interaction between the residues of LILRB2 D1 and that of HLA-G1. The pink dotted line represents the polar interaction between the residues
of LILRA3 D1 and that of HLA-G1.
doi:10.1371/journal.pone.0019245.g005
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LILRB1/HLA-A*0201 and LILRB2/HLA-G1 clearly demon-
strates that LILRA3 may binds to both classical and non-classical
HLAIs and also explains well why LILRA3 would binds better to
non-classical HLAIs than classical HLAIs. These conclusions are
consistent with the SPR results.
Key residues or structural elements crucial for influencing
the binding affinity between Group 1 LILRs and HLAIs
As mentioned above, the changes of the amino acids at positions
36 and 76 between LILRA3 (His36 and Ile76) and LILRB1
(Arg36 and Tyr76) are one of the important reasons for the
reduced binding affinity of LILRA3 to HLA-A*0201 compared to
that of LILRB1 to HLA-A*0201. However, these changes do not
affect the interaction between LILRA3 D1 and HLA-G1 because
they favor the LILRB2/HLA-G1 binding mode. Leu37 in both
LILRB2 and LILRA3 forms a hydrophobic interaction with
Tyr197 of the a3 domain of HLA-G1, and Tyr76 does not
participate in the interaction between LILRB2 and HLA-G1.
Among Group 1 members, only LILRA3 and LILRA2 have a
histidine at position 36. Other Group 1 members, including
LILRA1, have Arg36 that fully interacts with Asp196 of HLA-
A*0201. Therefore, we predict that LILRA1 will interact better
with HLA-A*0201 than LILRA3.
Again, the self-interaction between LILRA3 D1 Lys42 and
Glu68 is the other key structural difference that reduces the
binding affinity of LILRA3 to HLA-A*0201 compared to that of
LILRB1 to HLA-A*0201. The relatively rigid conformation of
Lys42 due to the interaction with Glu68 makes it impossible for
Lys42 to interact with Asp96 of the a3 domain of HLA-A*0201.
However, in the LILRB2/HLA-G1 binding mode, Lys42 forms a
hydrogen bond with Glu229 of the b2m of HLA-G1, as well as
with Glu68 of LILRA3 D1.
Despite the high sequence similarity around Glu68 and Lys42
among LILRA3, LILRB1 and LILRB2, it is not clear why the
Lys42 of LILRB1 and B2 do not form a self-interaction with
Glu68. Figure 6 shows the detailed structure around Lys42 and
Trp67 in the LILRA3 D1/LILRB1 D1 (Fig. 6A) and LILRA3
D1/LILRB2 D1 (Fig. 6B) structures. In all of the reported single
crystal structures of LILRB1 D1D2 (1GOX, 1UFU, and 1UGN)
and the co-crystal structure of LILRB1/HLA-A*0201, the
peptide backbone carbonyl of LILRB1 D1 Glu40 forms a
hydrogen bond with the nitrogen of the backbone amino group of
Lys42, but in LILRA3 D1, there is no such interaction.
Consequently, the loop of LILRA3 D1 between the C strand
and 310 helix 1 is relatively more flexible than that of LILRB1
D1, and the Lys42 on that loop may be able to form a hydrogen
bond with Glu68 of the third 310 helix of LILRA3 D1 (Fig. 6A).
Contrary to this, LILRB1 D1 Lys42 is relatively rigid (due to its
hydrogen bond with Glu40), and may be oriented only toward
Asp96 of the b2m of HLA-A*0201. Meanwhile, in LILRB2 D1,
there is no polar interaction between the backbones of Glu40 and
Lys42, so the loop in question is flexible, as in LILRA3 D1.
However, as shown in Figure 6B, there is also no hydrogen bond
between Lys42 and Glu68 of LILRA3 D1. Additionally, the
amino acids at position 70 are different between LILRA3 and
LILRB2 (Ala and Thr, respectively), and the third 310 helix
structures are different, especially from the torsion angles between
LILRA3 and LILRB2. Further, the orientations of Glu68 are
quite different between LILRA3 and LILRB2; Glu68 of LILRB2
points toward the opposite direction of Lys42, making self-
interaction impossible in LILRB2. Thus, though Group 1 LILRs
display high amino acids conservation, one or two amino acid
differences in the binding region or its adjacent region greatly
influence the binding affinities for classical and non-classical
HLAIs.
Figure 6. Comparison of the conformation of Lys42 of LILRB1 (green), LILRB2 (yellow), and LILRA3 (magenta) in complex with HLA-
A*0201 or HLA-G1. A. Self-interaction of Lys42 with Glu68 in LILRA3 (pink dotted line) and the interaction of Lys42 of LILRB1 with Asp96 of the b2m
of HLA-A*0201 in LILRB1/HLA-A*0201 (green dotted line). Cyan and brown represent the a3 domain and the b2m of HLA-A*0201, respectively. B. Self-
interaction of Lys42 with Glu68 in LILRA3 (pink dotted line) and the interaction of Lys42 of LILRA3 (pink dotted line) and LILRB2 (yellow dotted line)
with Glu227 of the a3 domain of HLA-G1. Cyan and brown represent the a3 domain and the b2m of HLA-G1, respectively.
doi:10.1371/journal.pone.0019245.g006
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In this paper, we characterized the binding properties to HLAIs
and D1 domain structure of LILRA3, an activating LILR Group 1
member. Our studies of LILRA3/HLAIs binding properties using
BIAcoreH SPR clearly demonstrated that LILRA3 binds both
classical and non-classical HLAIs with reduced affinities compared
to LILRB1/HLA-A*0201 and LILRB2/G1 binding. The crystal
structureofLILRA3D1alsosupportstheseresults.Bycomparingthe
b i n d i n gr e g i o no fL I L R A 3D 1w i t hL I L R B 1D 1a n dL I L R B 2D 1i n
the free structures or those complexed with HLAIs, the following
conclusion can be drawn. First, as predicted, LILRA3 contains the
fundamental fold for HLAI biding. Because it contains 310 helices
region located between the C and E strands of D1 and a hydrophobic
core consisting of the helices and C and E strands, LILRA3 D1 can
binds abroad range of classical and non-classical HLAIs. Second, one
or two amino acid changes in the binding region of LILRA3
compared to LILRB1 and B2 reduce the binding affinity of LILRA3
to classical HLAIs relative to other Group 1 LILRs. Third, the self-
interaction between Lys42 and Glu68 is unique to LILRA3 D1, and
this property may be an important reason why the HLAI binding
affinity of LILRA3 is reduced than that of LILRB1 and B2. In any
event, LILRA1 follows this rule: if it displays self-interaction of Lys42
with Glu68, the binding affinity may be reduced relative to LILRB1
or B2. If not, the affinity will be greater than that of LILRA3. Indeed,
on-going studies of the relationship between the binding affinity to
HLAIs and the structure of LILRA1 will address this hypothesis.
LILRA3 is the only secretory LILR, and it is expressed by
monocytes, macrophages, and dendritic cells, though mainly by
macrophages [9,24]. From a functional viewpoint, LILRA3 may
greatly control the inhibition of the immune response induced by
LILRB1, LILRB2, and other HLA-binding LILR molecules like
LILRA1. However, why immune cells express different Group 1
LILRswithvariousbindingaffinities to a broadrange ofHLAIsand
what is the important role of LILRA3 in macrophages must be
addressed in the future. The crystal structure of the D1 domain and
the SPR binding properties of LILRA3 indicated that LILRA3
binds HLA-G1 preferentially over HLA-A*0201, which explains its
possible function in fetal-maternal immune control [34]. Indeed,
b2m-free heavychains(fHCs)ofHLA-G1arefoundintheplacenta,
and LILRA1 and LILRB2 can bind fHC tetramers of HLA-B27
and HLA-G1 [35]. The amino acid sequence alignment of Group 1
LILRs also predicts that LILRA3 recognizes classical HLAIs less
well than LILRA1, LILRB1, and B2, as well as that LILRA3 may
recognize the fHCs of classical HLAIs. This implies that LILRA3
would play an important role in the strictinhibitorycontrolbetween
classicaland non-classicalHLAIs.Interestingly,whileinthe revision
process of this manuscript, Jones et al have just published the data
showing that LILRA3 preferentially binds to HLA-C free heavy
chain [36]. Thus, expression of LILRs with various affinities to
different types of classical and non-classical HLAIs on a certain
tissue or cell seems make the delicate organization of the immune
response in the human body possible [2,37]. Indeed, comparing the
binding affinities between various LILR Group 1 members and
multiple types of classical and non-classical HLAIs, as well as the
possible role of LILRA3 in the inhibitory equilibrium, deserve
considerable attention in the future.
Materials and Methods
Construction of the recombinant plasmids for LILRA3 D1
and D1D2
The full-length LILRA3 gene (containing D1–D4 and the stalk
sequence) was cloned from a human lymphocyte cDNA library, as
previously described [31,38]. The primers used in the PCR
amplification are as follows:
Forward primer=ACCCCCATCCTCACGGTCC, and
Reverse Primer=CTCACCAGCC TTGGAGTCGGA.
DNA fragments encoding the LILRA3 D1 and D1D2 regions
(D1, 1–97; and D1D2, 1–197) were sub-cloned from the full-
length gene, using the following primers:
D1/D1D2 Forward primer=GGAATTCCATATGGGGCCG-
CTCCCGAAGCCGACCC,
D1 Reverse Primer=CCGCTCGAGTTATCCTGTCACCAC-
CAGCTCCAGGGGGT, and
D1D2 Reverse primer=CCGCTCGAGTTAACCTGGGAC-
CAGGAGCCCCAGG.
In all forward and reverse primers, a start or stop codon was
introduced with NdeIo rXhoI restriction sites accordingly. All of the
PCR products were ligated into the pET21a vector (Novagen),
transformed into E. coli strain BL21 (DE3) pLysS, and expressed in
the form of inclusion bodies.
Protein preparation of LILRA3 D1, LILRA3 D1D2, LILRB2
D1D2, HLA-A*0201 and HLA-G1
Full-length LILRB2DNAwas kindly providedfrom Dr.Katsumi
Maenaka, and the recombinant clone of its D1D2 region was
prepared as previously reported [20]. The clones of the recombi-
nant HLA-A*0201 and HLA-G1 were previously prepared [39].
All proteins were expressed in E. coli strain BL21 (DE3) pLysS
and purified as previously reported [39,40]. The inclusion body
solution was injected into refolding buffer containing 100 mM Tris-
HCl (pH 8.0), 2 mM EDTA, 400 mM L-arginine-HCl, 0.5 mM
oxidized glutathione, 5 mM glutathione, 0.1 mM PMSF, and
0.1 mM NaN3. To purify the HLA-A2 and HLA-G1, the inclusion
body solution of b2m and peptide (TLACFVLAAV, derived from
human SARS-CoV membrane protein for HLA-A*0201; and
RIIPRHLQL, derived from cellular endogenous protein histone for
HLA-G1) dissolved in DMSO, were injected into the refolding
buffer, and then the inclusion body solution of the heavy chain was
later injected into the refolding buffer. The refolding solution was
concentrated using a Stirred Cell and ultracentrifugal filter devices
(Millipore). All proteins were purified by size exclusion chromatog-
raphy using a Superdex 75 10/300 GL column (GE Healthcare),
equilibrated in Tris-HCl (pH 8.0) buffer with an A ¨CTA FPLC
(Amersham Biosciences). For LILRA3 D1 and D1D2, the buffer
was exchanged gradually to BIAcore buffer (HEPES, pH 7.4) and
finally filtered on 200 10/300 GL column (GE Healthcare). For
HLA-A*0201 and HLA-G1, the proteins were further purified by
anion exchange chromatography (Resource Q) followed by final gel
filtrationonsuperdex20010/300GLcolumn(GEHealthcare)with
BIAcore buffer (HEPES, pH 7.4). For ILT4 D1D2, it was also
further purified by cation exchange chromatography (Source Q)
followed by final gel filtration on superdex 200 10/300 GL column
(GE Healthcare) with BIAcore buffer (HEPES, pH 7.4). The size
exclusion chromatogram and the 12% SDS-PAGE of the main
fractions confirmed the monomeric state of LILRB2 D1D2, HLA-
A*0201, and HLA-G1.
Crystallization of LILRA3 D1, data collection, phasing, and
refinement
Despite efforts to crystallize LILRA3 D1D2, we failed to obtain
any diffractive crystals. Therefore, we focused on crystal trials of
LILR D1. The purified LILRA3 D1 was concentrated and
adjusted to 15 mg/ml with elution buffer (50 mM NaCl, 20 mM
Tris-HCl, pH 8.0), and crystallization was attempted at 18uC
using the hanging drop vapor diffusion method. Crystallization
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using 1.0 M ammonium sulfate, 0.1 M HEPES buffer (pH 7.5),
and 0.75% (w/v) PEG8000.
The LILRA3 D1 crystal was cryoprotected in mother liquor
containing 15% glycerol before being flash-cooled in liquid
nitrogen. Diffraction data were collected using an in-house X-
ray source (Rigaku MicroMax007 desktop rotating-anode X-ray
generator with a Cu target operated at 40 kV and 30 mA) and an
R-AXIS IV++ imaging-plate detector at a wavelength of
1.5418 A ˚. The collected intensities were indexed, integrated,
corrected for absorption, scaled, and merged using HKL-2000.
Data collection and processing statistics are summarized in
Table 1.
The structure of LILRA3 D1 was solved by the molecular
replacement method using Phaser [41] from the CCP4 program
suite [42] with the structure of LILRB2 (PDB code: 1VDG) as a
search model. Initial restrained rigid-body refinement and manual
model building were performed using REFMAC5 [43] and
COOT [44], respectively. Further rounds of refinement were
performed using the phenix.refine program, implemented in the
PHENIX package [45], with coordinate refinement, isotropic
ADP refinement, and bulk solvent modeling. The stereochemical
quality of the final model was assessed with the PROCHECK
program [46]. All of the presented structural figures were
produced using PyMol (http://pymol.sourceforge.net).
BIAcoreH SPR analysis of LILRA3 D1 and D1D2
BIAcoreH3000 was used to study the direct binding of LILRA3
D1 and D1D2 to HLA-A*0201 and HLA-G1. HLA-A*0201 and
HLA-G1, as well as control protein (BSA), were individually
immobilized (700, 300 and 700 resonance units (RU) respectively)
by amine group coupling on research grade CM5 sensor chips at
pH 5.0. LILRB2 D1D2, LILRA3 D1 and LILRA3D1D2 in
HEPES buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM
EDTA, and 0.005% (v/v) Tween-20) were then injected over the
immobilized HLAIs at 25uC. Kinetic constants (Kd) were derived
by Scatchard analysis or nonlinear curve fitting of the standard
Langmuir binding isotherm using BIAevaluation version 4.1
(BIAcoreH).
Protein Data Bank accession number
The atomic coordinates of LILRA3 D1 have been deposited in
the RCSB Protein Data Bank with accession code of 3Q2C.
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